Royal College of Nursing launches framework to improve care for liver disease patients
Wednesday, 07 October 2015 11:52
The Royal College of Nursing (RCN) has launched a revised competence framework to help improve nursing care for people with liver disease. The framework, published on 18th September and launched at the British Liver Nurses' Forum 17th Annual Conference, aims to promote education and training in this area.
The framework is authored by RCN members Lynda Greenslade, Clinical Nurse Specialist in Hepatology at the Royal Free London NHS Foundation Trust, and Michelle Clayton, Lecturer in Liver Care at the University of Leeds. It describes the professional standards expected of practitioners when caring for adults and young people across England with liver disease. The framework is applicable to nursing staff in primary and secondary care settings, and is also suitable for use by healthcare practitioners such as GPs and liver dieticians.
The framework also highlights how liver disease was formerly considered to be a rare disease, but now is the fifth most common cause of death in the UK, namely as a result of alcohol, viral hepatitis and obesity leading to non-alcoholic fatty liver disease (NAFLD).
IBD Registry News – October 2015
Wednesday, 07 October 2015 10:23
Following the successful workshops run by the IBD Audit team in March, we are running a series of regional meetings to give protected time to IBD clinical teams to plan their next steps for local quality improvement. The meetings have been developed with the help of the Audit team and aim to demonstrate how Registry participation will contribute to service development. A representative from the IBD Audit team will be present at each of the meetings. Half-day meetings will be held in:
CARDIFF Thursday 19th November Chair: Dr Barney Hawthorne
TAUNTON Friday 20th November Chair: Dr Ian Shaw
LONDON Friday 4th December Chair: Dr Stuart Bloom
WARRINGTON Monday 7th December Chair: Dr Keith Bodger
BIRMINGHAM Wednesday 9th December Chair: Prof Tariq Iqbal
DARLINGTON Spring 2016 Chair: Dr John Mansfield
GLASGOW Spring 2016 Chair: Dr Ian Arnott
Members of the Registry team will advise on how to get started with the Registry, in preparation for next year when it will become the vehicle for the collection of national audit data. For more information and to register please go to http://ibdregistry.org.uk/
National survey on faecal transplantation for C. difficile
Thursday, 01 October 2015 10:46
We would be grateful if you could kindly spare 2 minutes of your time to participate in this very short national survey exploring your centre's practices for faecal microbiota transplantation (FMT). To date there has been very limited experience of its use the United Kingdom for treating recurrent and refractory Clostridium difficile infection and the reasons for this remain unclear. It is also apparent from published studies that the patient and donor selection criteria, stool characteristics and mode of administration are not standardised and vary from centre to centre. We intend to survey the practices of faecal transplantation for Clostridium difficile infection across the UK and understand barriers involved in setting this up locally. We would really appreciate your help in this. This survey is led by Professor Tariq Iqbal (University Hospital Birmingham), Dr Ailsa Hart (St Marks Hospital), Dr Alaric Colville (Royal Devon and Exeter Hospital), Professor Peter Hawkey (University of Birmingham) and Dr Horace Williams (Imperial College Healthcare Trust). The survey is split into two parts. The first part involves a very short online survey (which closes 31 October); if you agree to take part in the second part of the survey, we would then contact you for 5 minute phone conversation.
M Nabil Quraishi
University Hospital Birmingham
Fourth report of the biological therapy element of the UK IBD audit
Thursday, 24 September 2015 14:32
Latest UK IBD audit report shows further improvement for patients following treatment with biological therapies
The UK inflammatory bowel disease (IBD) clinical audit report reveals today that the majority of patients (80% adult and 77% paediatric) with Crohn's disease saw an improvement following biological therapies
This is the fourth report of the biological therapy element of the UK IBD audit. The purpose of this audit is to measure the efficacy, safety and appropriate use of the biological therapies infliximab and adalimumab, also known as anti-TNFα drugs, in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.
The data presented in the reports demonstrate that biological therapies for IBD are effective and relatively safe treatments. Patterns of use are changing, with earlier use in patients with less severe disease. It is likely that this reflects more appropriate prescribing as physicians become more familiar with these drugs.
National and executive summary versions of both adult and paediatric reports are available on the Royal College of Physicians' website:
Page 1 of 7